Non Small Cell Lung Cancer Clinical Trials

204 studies are recruiting for non small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 4

1. A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

   Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Highlands Oncology Group - Springdale /ID# 277132, Springdale, Arkansas

   Locations

   117 in total

   Run by

   AbbVie

   See if you can join NCT07155187 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of San Diego Moores Cancer Center, La Jolla, California

   Locations

   76 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

   The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Hospital, Houston, Texas

   Locations

   2 in total

   Run by

   Shanghai Henlius Biotech

   See if you can join NCT06907615 on ClinicalTrials.gov

4. Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

   The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Run by

   Stanford University

   See if you can join NCT04585490 on ClinicalTrials.gov

5. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

   Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (N…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Palo Verde Hematology Oncology, Glendale, Arizona

   Locations

   159 in total

   Run by

   Nuvalent Inc.

   See if you can join NCT06765109 on ClinicalTrials.gov

6. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

   Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Gilbert, Arizona

   Locations

   20 in total

   Run by

   AstraZeneca

   See if you can join NCT05877599 on ClinicalTrials.gov

7. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Alabama Oncology, Birmingham, Alabama

   Locations

   158 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06881784 on ClinicalTrials.gov

8. DK222 Study at Hopkins

   This Phase 1 clinical trial will test a new drug called [18F]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the body, how long it stays in the body, and how much radiation it gives off. [18F]DK222 is designed to attach strongly and specifically to a prot…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Johns Hopkins Hospital, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT07140315 on ClinicalTrials.gov

9. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

   Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Duarte, California

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT06218914 on ClinicalTrials.gov

10. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's i…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Providence Medical Foundation, Fullerton, California

    Locations

    389 in total

    Run by

    Pfizer

    See if you can join NCT06758401 on ClinicalTrials.gov

11. Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery

    The goal of the trial is to test the usability, feasibility and acceptability of an unsupervised, appbased yoga program for participants undergoing thoracic RT and their caregivers.

    Stage

    Not phased

    Ages

    18 and older

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06919874 on ClinicalTrials.gov

12. Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

    The goal of this clinical research study is to find a safe and tolerable dose of navlimetostat in combination with pumitamig that can be given to patients with MTAP-deficient advanced non-small cell lung cancer (NSCLC). The effectiveness of the study drugs will also be studied.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UT MD Anderson, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07579221 on ClinicalTrials.gov

13. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

    This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Precision NextGen Oncology, Beverly Hills, California

    Locations

    8 in total

    Run by

    Neonc Technologies, Inc.

    See if you can join NCT06047379 on ClinicalTrials.gov

14. Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

    The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Pacific Cancer Care, Monterey, California

    Locations

    10 in total

    Run by

    N-Power Medicine

    See if you can join NCT07028489 on ClinicalTrials.gov

15. Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

    This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired. People may be eligible for this study if they have advanced stage NSCLC and feel short of breath some of t…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio

    Run by

    Case Comprehensive Cancer Center

    See if you can join NCT07104630 on ClinicalTrials.gov

16. An External Control Arm Study in Non-Small Cell Lung Cancer

    A study to create control arms using current and future information in patients with lung cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Pacific Cancer Care, Monterey, California

    Locations

    11 in total

    Run by

    N-Power Medicine

    See if you can join NCT07174388 on ClinicalTrials.gov

17. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beverly Hills Cancer Center, Beverly Hills, California

    Locations

    37 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

18. Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

    This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and ca…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    3 in total

    Run by

    Washington University School of Medicine

    See if you can join NCT06529822 on ClinicalTrials.gov

19. Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

    This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    11 in total

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06745882 on ClinicalTrials.gov

20. A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

    A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists & Research Institute - Sarasota, Sarasota, Florida

    Locations

    16 in total

    Run by

    Blueprint Medicines Corporation

    See if you can join NCT07629960 on ClinicalTrials.gov

21. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

    This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sylvester Comprehensive Cancer Center - Miami, Miami, Florida

    Locations

    17 in total

    Run by

    Aulos Bioscience, Inc.

    See if you can join NCT05267626 on ClinicalTrials.gov

22. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Clinical Study Site, Chandler, Arizona

    Locations

    285 in total

    Run by

    Summit Therapeutics

    See if you can join NCT06767514 on ClinicalTrials.gov

23. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administe…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    14 in total

    Run by

    Aktis Oncology, Inc.

    See if you can join NCT07020117 on ClinicalTrials.gov

24. Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

    To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT05681780 on ClinicalTrials.gov

25. A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

    The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07323732 on ClinicalTrials.gov